Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/22/25
End: 12/01/27
Due: 12/01/28
Phase: N/A
Priority: Normal
Start: 03/30/23
End: 11/30/25
Due: 11/30/26
Phase: N/A
Priority: Normal
Start: 07/24/23
End: 12/31/27
Due: 12/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | NCT06669975 | AP Biosciences Inc. | user2@example.com | None | 2025-04-22 | 2027-12-01 | 2028-12-01 | - | - | 2025-07-14 |
| A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors | NCT06723964 | AP Biosciences Inc. | user2@example.com | None | 2023-03-30 | 2025-11-30 | 2026-11-30 | - | - | 2025-07-14 |
| A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies | NCT05473156 | AP Biosciences Inc. | user2@example.com | None | 2023-07-24 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |